Literature DB >> 15205870

Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats.

Jane Gartlon1, Philip Szekeres, Mark Pullen, Henry M Sarau, Nambi Aiyar, Usman Shabon, David Michalovich, Klaudia Steplewski, Cathy Ellis, Nabil Elshourbagy, Mark Duxon, Tracey E Ashmeade, David C Harrison, Paul Murdock, Shelagh Wilson, Abdel Ennaceur, Alan Atkins, Christian Heidbreder, Jim J Hagan, A Jackie Hunter, Declan N C Jones.   

Abstract

RATIONALE: Neuromedin-U (NmU) is an agonist at NMU1R and NMU2R. The brain distribution of NmU and its receptors, in particular NMU2R, suggests widespread central roles for NmU. In agreement, centrally administered NmU affects feeding behaviour, energy expenditure and pituitary output. Further central nervous system (CNS) roles for NmU warrant investigation.
OBJECTIVES: To investigate the CNS role of NmU by mapping NMU1R and NMU2R mRNA and measuring the behavioural, endocrine, neurochemical and c-fos response to intracerebroventricular (i.c.v.) NmU.
METHODS: Binding affinity and functional potency of rat NmU was determined at human NMU1R and NMU2R. Expression of NMU1R and NMU2R mRNA in rat and human tissue was determined using semi-quantitative reverse-transcription polymerase chain reaction. In in-vivo studies, NmU was administered i.c.v. to male Sprague-Dawley rats, and changes in grooming, motor activity and pre-pulse inhibition (PPI) were assessed. In further studies, plasma endocrine hormones, [DOPAC + HVA]/[dopamine] and [5-HIAA]/[5-HT] ratios and levels of Fos-like immunoreactivity (FLI) were measured 20 min post-NmU (i.c.v.).
RESULTS: NmU bound to NMU1R ( K(I), 0.11+/-0.02 nM) and NMU2R ( K(I), 0.21+/-0.05 nM) with equal affinity and was equally active at NMU1R (EC(50), 1.25+/-0.05 nM) and NMU2R (EC(50), 1.10+/-0.20 nM) in a functional assay. NMU2R mRNA expression was found at the highest levels in the CNS regions of both rat and human tissues. NMU1R mRNA expression was restricted to the periphery of both species with the exception of the rat amygdala. NmU caused a marked increase in grooming and motor activity but did not affect PPI. Further, NmU decreased plasma prolactin but did not affect levels of corticosterone, luteinising hormone or thyroid stimulating hormone. NmU elevated levels of 5-HT in the frontal cortex and hypothalamus, with decreased levels of its metabolites in the hippocampus and hypothalamus, but did not affect dopamine function. NmU markedly increased FLI in the nucleus accumbens, frontal cortex and central amygdala.
CONCLUSIONS: These data provide further evidence for widespread roles for NmU and its receptors in the brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205870     DOI: 10.1007/s00213-004-1918-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  Localization of 7B2, neuromedin B, and neuromedin U in specific cell types of rat, mouse, and human pituitary, in rat hypothalamus, and in 30 human pituitary and extrapituitary tumors.

Authors:  J H Steel; S Van Noorden; J Ballesta; S J Gibson; M A Ghatei; J Burrin; U Leonhardt; J Domin; S R Bloom; J M Polak
Journal:  Endocrinology       Date:  1988-01       Impact factor: 4.736

2.  Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity.

Authors:  D N Jones; J Gartlon; F Parker; S G Taylor; C Routledge; P Hemmati; R P Munton; T E Ashmeade; J P Hatcher; A Johns; R A Porter; J J Hagan; A J Hunter; N Upton
Journal:  Psychopharmacology (Berl)       Date:  2001-01-01       Impact factor: 4.530

3.  Identification of receptors for neuromedin U and its role in feeding.

Authors:  A D Howard; R Wang; S S Pong; T N Mellin; A Strack; X M Guan; Z Zeng; D L Williams; S D Feighner; C N Nunes; B Murphy; J N Stair; H Yu; Q Jiang; M K Clements; C P Tan; K K McKee; D L Hreniuk; T P McDonald; K R Lynch; J F Evans; C P Austin; C T Caskey; L H Van der Ploeg; Q Liu
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

4.  Neuromedin U acts in the central nervous system to inhibit gastric acid secretion via CRH system.

Authors:  Muhtashan S Mondal; Yukari Date; Noboru Murakami; Koji Toshinai; Takuya Shimbara; Kenji Kangawa; Masamitsu Nakazato
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-02-12       Impact factor: 4.052

5.  Orexin A activates locus coeruleus cell firing and increases arousal in the rat.

Authors:  J J Hagan; R A Leslie; S Patel; M L Evans; T A Wattam; S Holmes; C D Benham; S G Taylor; C Routledge; P Hemmati; R P Munton; T E Ashmeade; A S Shah; J P Hatcher; P D Hatcher; D N Jones; M I Smith; D C Piper; A J Hunter; R A Porter; N Upton
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

6.  Serotonin2/1C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres.

Authors:  R A Leslie; J M Moorman; A Coulson; D G Grahame-Smith
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

7.  Structure-activity relationships of rat neuromedin U for smooth muscle contraction.

Authors:  N Sakura; S Ohta; Y Uchida; K Kurosawa; K Okimura; T Hashimoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1991-08       Impact factor: 1.645

8.  Primary structure of neuromedin U from the rat.

Authors:  J M Conlon; J Domin; L Thim; V DiMarzo; H R Morris; S R Bloom
Journal:  J Neurochem       Date:  1988-09       Impact factor: 5.372

9.  Regional hemodynamic effects of neuromedin U in conscious rats.

Authors:  S M Gardiner; A M Compton; T Bennett; J Domin; S R Bloom
Journal:  Am J Physiol       Date:  1990-01

10.  Hypothalamic actions of neuromedin U.

Authors:  A M Wren; C J Small; C R Abbott; P H Jethwa; A R Kennedy; K G Murphy; S A Stanley; A N Zollner; M A Ghatei; S R Bloom
Journal:  Endocrinology       Date:  2002-11       Impact factor: 4.736

View more
  25 in total

1.  Neuromedin S and U.

Authors:  Colleen M Novak
Journal:  Endocrinology       Date:  2009-07       Impact factor: 4.736

2.  Gamma-Aminobutyric Acidergic Projections From the Dorsal Raphe to the Nucleus Accumbens Are Regulated by Neuromedin U.

Authors:  James M Kasper; David L McCue; Adrianna J Milton; Angelia Szwed; Catherine M Sampson; Mei Huang; Susan Carlton; Herbert Y Meltzer; Kathryn A Cunningham; Jonathan D Hommel
Journal:  Biol Psychiatry       Date:  2016-03-08       Impact factor: 13.382

3.  Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.

Authors:  T Kaisho; H Nagai; T Asakawa; N Suzuki; H Fujita; K Matsumiya; N Nishizawa; Y Kanematsu-Yamaki; K Dote; J-I Sakamoto; T Asami; S Takekawa
Journal:  Int J Obes (Lond)       Date:  2017-07-31       Impact factor: 5.095

Review 4.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

5.  Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding.

Authors:  Hongkui Zeng; Alexander Gragerov; John G Hohmann; Maria N Pavlova; Brian A Schimpf; Hui Xu; Long-Jun Wu; Hiroki Toyoda; Ming-Gao Zhao; Alex D Rohde; Galina Gragerova; Rene Onrust; John E Bergmann; Min Zhuo; George A Gaitanaris
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

Review 6.  Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.

Authors:  J D Mitchell; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

7.  The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

Authors:  Andrea Peier; Jennifer Kosinski; Kimberly Cox-York; Ying Qian; Kunal Desai; Yue Feng; Prashant Trivedi; Nicholas Hastings; Donald J Marsh
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

8.  Sensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesity.

Authors:  Colleen M Novak; Minzhi Zhang; James A Levine
Journal:  Brain Res       Date:  2007-07-13       Impact factor: 3.252

9.  A Zebrafish Genetic Screen Identifies Neuromedin U as a Regulator of Sleep/Wake States.

Authors:  Cindy N Chiu; Jason Rihel; Daniel A Lee; Chanpreet Singh; Eric A Mosser; Shijia Chen; Viveca Sapin; Uyen Pham; Jae Engle; Brett J Niles; Christin J Montz; Sridhara Chakravarthy; Steven Zimmerman; Kourosh Salehi-Ashtiani; Marc Vidal; Alexander F Schier; David A Prober
Journal:  Neuron       Date:  2016-02-17       Impact factor: 17.173

10.  Appetite-modifying actions of pro-neuromedin U-derived peptides.

Authors:  David A Bechtold; Tina R Ivanov; Simon M Luckman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.